Navigation Links
Today's Research on PDL BioPharma, Dendreon, Medivation, ACADIA Pharma, and Cell Therapeutics
Date:3/6/2013

LONDON, March 6, 2013 /PRNewswire/ --

On Tuesday, the markets retained their bullish mode as indices created yet another life-time high. The markets showed across the board improvement, and the Healthcare sector saw Johnson & Johnson creating a new all time high. The Dow Jones ended its latest session at 14,253.77, up 0.89 percent while NASDAQ was up 1.32 percent to close at 3,224.13. Similarly, S&P closed on a positive note at 1,539.79, up 0.96 percent. Our research team took a look at the Healthcare sector, focusing on the biotech Industry which includes major companies like PDL BioPharma Inc. (NASDAQ: PDLI), Dendreon Corporation (NASDAQ: DNDN), Medivation Inc. (NASDAQ: MDVN), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) and Cell Therapeutics Inc. (NASDAQ: CTIC). StockCall professionals have completed their technical analysis on PDLI, DNDN, MDVN, ACAD and CTIC and these free reports are accessible by registering at

http://www.stockcall.com/research  

On top of ending its previous trading session flat, PDL BioPharma Inc. is still down 0.85 percent for the year. However, the stock has grown 6.16 percent in the past 52 weeks. PDLI closed flat at $6.98 on volume of 2.56 million shares on Tuesday. Its average trading volume stands at 2.01 million shares. PDL BioPharma's shares currently face resistance at around $7.04. The stock has support at around $6.89. It is currently trading above its 20-day, but below 50-day moving averages, which is a neutral signal. Sign up for the free technical research on PDLI at

http://www.StockCall.com/PDLI030613.pdf

Dendreon Corporation traded in the range of $5.61 and $5.85 during Tuesday's trading session. It opened at $5.75 and closed at $5.70, down 0.35 percent. The stock is currently in a neutral mode and has its first resistance level at $5.80. Upon breaching this level, the company may go as high as $6.03. It traded 3.47 million shares and is above its 20-day moving average price. Its first support level is at $5.42. So far in 2013, the stock is up 7.75 percent. Be sure to read our latest technical research on DNDN by registering at

http://www.StockCall.com/DNDN030613.pdf

Despite the upward movement shown by broad market indices, Medivation Inc.'s stock finished 2.47 percent lower at $45.86, with volume up from daily average of 1.50 million to 3.64 million. The biotech company's stock is down so far in 2013 with a year-to-date decline at 10.36 percent. However, the stock currently shows a bearish trend which is further confirmed by the stock's MACD chart. Medivation has its first support level at $43.26. In the coming trading sessions, the stock is likely to go as high as $49.09. Sign up and read the complimentary report on MDVN at

http://www.StockCall.com/MDVN030613.pdf

ACADIA Pharmaceuticals Inc.'s stock rose mildly in its latest trading session. The stock closed 0.63 percent higher at $6.37 with 1.48 million share volume. Despite the mild upward movement, the stock is still up more than 36 percent for the year. In the past 52 weeks, the company's stock is up 300 percent. The stock currently has support at $6.28 level. The stock's MACD chart shows a neutral trend. ACADIA may face its first resistance level at $6.75. Upon breaching this level, the stock may go as high as $7.03. The free report on ACAD can be downloaded by signing up now at

http://www.StockCall.com/ACAD030613.pdf

Shares of Cell Therapeutics Inc. ended flat in Tuesday's trading session. The stock closed at $1.26 on below average volume of 966,000 shares. The company's shares have lost more than 3 percent this year, underperforming the broad market. It has support at $1.15. Despite the flat ending, Cell Therapeutics' shares are still trading below their 50-day and 200-day moving averages. Free report on CTIC can be accessed by registering at

http://www.StockCall.com/CTIC030613.pdf

About StockCall.com

StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines. Sign up today to talk to our financial analyst at

http://www.stockcall.com  


'/>"/>
SOURCE StockCall.com
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Army Researcher Develops Potential Vaccine Carrier That May Give Stockpiling Efforts A Shot In The Arm
2. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
3. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
4. Southern Research Signs Agreement with Apath, LLC to Conduct Preclinical Studies with Virus-Based HCV Screenings
5. Galenea to Receive $6 Million From The Stanley Medical Research Institute to Progress Pro-Cognitive Drug Discovery and Development Program
6. Upsher-Smith Research Shows Unique Pharmacokinetic Profile of USL255 Extended Release Topiramate
7. Biomedical Advanced Research and Development Authority (BARDA) Exercises Option with Pfenex Inc. To Extend Contract for the Development of a Recombinant Protective Antigen (rPA) Based Anthrax Vaccine
8. ResearchMoz: The World Anesthesia Drug Market (General, Local, Adjunctive) - Market Research Report
9. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
10. ResearchMoz: Telemedicine Monitoring Market Shares, Strategies, and Forecasts, Worldwide, 2012 to 2018 - Market Research Report
11. Okuma America Chooses The Daniel Group To Provide Customer Service Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... /PRNewswire/ - Medicure Inc. ("Medicure") (TSXV:MPH, OTC:MCUJF), a specialty ... year ended December 31, 2016 after market close ... being released later than the previous fiscal year,s ... operations and balances of Apicore from the acquisition ... filing date meets TSX Venture Exchange listed company ...
(Date:3/28/2017)... 28, 2017 The global emerging cancer diagnostics ... 13.45% from 2016 to 2023 and reach a figure ... Cancer is a chronic disease and is affecting a ... diagnostics market. This report is focused on emerging cancer ... growth is propelled due to factors such as: increasing ...
(Date:3/28/2017)... SPRING, Md. , March 28, 2017 /PRNewswire-USNewswire/ ... approved Dupixent (dupilumab) injection to treat adults with ... patients whose eczema is not controlled adequately by ... are not advisable. Dupixent can be used with ... of Dupixent demonstrates our commitment to approving new ...
Breaking Medicine Technology:
(Date:3/29/2017)... (PRWEB) , ... March 29, 2017 , ... VisualSP has ... sustainably. Until recently, the only option for on-premises installation of its Help System for ... required to install the system into the entire tenant. , The company recently ...
(Date:3/28/2017)... ... March 28, 2017 , ... India’s Chigurupati Technologies announced ... address the resolution to globally reduce the harmful use of alcohol set forth ... and TTB approved ingredients that when infused into alcohol, renders the alcohol liver ...
(Date:3/28/2017)... ... 29, 2017 , ... The Thyroid Secret is a specialized ... The program was recently launched on March 1, and Dr. Wentz discussed varied ... , Dr. Izabella Wentz is a licensed pharmacist and a foremost thyroid specialist. ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... the science and clinical practice of radiosurgery, announced today the publication of ... observational registry established to standardize data collection from patients treated with stereotactic ...
(Date:3/28/2017)... ... March 28, 2017 , ... WHO: , Dr. Paul Thomas; Dr. ... , Medical doctors and PhD scientists will speak to the press on behalf of ... support of an independent vaccine safety commission. , WHERE: , Zenger Room, National ...
Breaking Medicine News(10 mins):